Sectors
FCC Blocks New Foreign Drones: What It Means for DJI and U.S. Market
The FCC banned all new foreign-made drones from being registered in the U.S. in late 2025, a move that significantly affects Chinese manufacturers like DJI. Existing drone models can still be sold, especially since the Department of Commerce did not go forward with a full crackdown on Chinese drone imports. However, the ban essentially blocks…
Global Crypto Funds See Largest Weekly Exodus Since Nov 2025
World markets by TradingView Investors pulled $1.73 billion out of crypto investment products last week, the largest weekly decline since November 2025, according to a CoinShares report by head of research James Butterfill. The main reason seems to be ongoing pessimism. Investors are losing hope that interest rates will drop soon. Crypto prices are moving…
Breakthrough 140GHz Transceiver Could Rival Fiber Speeds
Researchers at the University of California, Irvine have built a wireless transceiver that runs at 140 GHz and can push data at 120 Gbps about 15 gigabytes per second. That’s far beyond what today’s Wi-Fi 7 or 5G mmWave can handle, which peak at 30 Gbps and 5 Gbps respectively. UC Irvine says this could…
Breakthrough Mapping Reveals Uranium Potential at Perch River
Fermi Exploration Ltd is making early but encouraging progress at its Perch River uranium property in Saskatchewan’s Athabasca Basin. This is one of the world’s top uranium districts, and recent work using Fleet Space Technologies’ ExoSphere platform has helped the company zero in on high-potential drill targets. For investors, the big takeaway is that Fermi…
GameStop Puts Bitcoin Back in Spotlight with $420M Coinbase Move
GME performance by TradingView GameStop (NYSE: GME) has quietly moved its entire Bitcoin position to Coinbase Prime, and it did not take long for speculation to follow. The transfer has led many investors to wonder whether the company is preparing to unwind its brief experiment with holding Bitcoin on the balance sheet. The company has…
Sanofi’s Amlitelimab Clears Regulatory Bar, Raises New Investor Doubts
SNY performance by TradingView Sanofi (NASDAQ: SNY, Euronext Paris: SAN)’s amlitelimab still looks like a viable U.S. approval candidate, but it is no longer the clear successor to Dupixent that investors once hoped for. The latest data keeps the program alive from a regulatory standpoint, yet introduces enough uncertainty that the stock is unlikely to…










